I actually see it the other way. I think combo will be harder to sell because there is already a treatment in place. Adding leronlimab on top of HAART increases cost, but how much does it help the patient?

When mono is available and HAART can be discontinued the cost is reduces and the patient experience is improved. I see this as easier to sell.

But I agree that Lero may become primarily a cancer drug.